[1]张 洁,齐红伟,丁北川,等.结核分枝杆菌临床分离株对吡嗪酰胺的药物敏感性分析[J].现代检验医学杂志,2017,32(03):49-51.[doi:10.3969/j.issn.1671-7414.2017.03.013]
　ZHANG Jie,QI Hong-wei,DING Bei-chuan,et al.Analysis on Pyrazinamide Drug Susceptibility of Mycobacterium Tuberculosis Clinical Strains[J].Journal of Modern Laboratory Medicine,2017,32(03):49-51.[doi:10.3969/j.issn.1671-7414.2017.03.013]
点击复制

结核分枝杆菌临床分离株对吡嗪酰胺的药物敏感性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年03期
页码:
49-51
栏目:
论著
出版日期:
2017-05-25

文章信息/Info

Title:
Analysis on Pyrazinamide Drug Susceptibility of Mycobacterium Tuberculosis Clinical Strains
文章编号:
1671- 7414(2017)03-049-03
作者:
张 洁1; 齐红伟2; 丁北川1; 王 民1; 武文清1
1.北京结核病控制研究所中心实验室，北京 100035；
2.北京市红十字 血液中心，北京 100088
Author(s):
ZHANG Jie1; QI Hong-wei2; DING Bei-chuan1; WANG Min1; WU Wen-qing1
1.Central Laboratory，Benjing Research Institute for Tuberculos is Control， Beijing 100035，China；
2.Beijing Red Cross Blood Center，Beijing 100088， China
关键词:
结核分枝杆菌; 吡嗪酰胺; 耐药性
分类号:
R378.911；R446.5
DOI:
10.3969/j.issn.1671-7414.2017.03.013
文献标志码:
A
摘要:
目的 研究结核分枝杆菌临床分离株对吡嗪酰胺(Pyrazinam ide，PZA)的药物敏感性，为结核病的临床用药和防治工作提供参考。方法 〖H T5”K〗应用Bactec MGIT 960系统，检测153株结核分枝杆菌对异烟肼 (isoniazid，INH)、 利福平(rifampicin，RFP)、乙胺丁醇(ethambutol，EMB)、链霉素(streptomycin，Sm)及PZ A的耐药性。结果 153株结核分枝杆菌中，PZA耐药34株，耐药率22 .2%，无PZA单耐药者。INH，RFP，EMB，Sm耐药和敏感患者的PZA耐药率分别为40.5%(34/8 4)，0％(0/69)；47.5 %(29/61)，5.4 %(5/92)；75%(6/8)，19.3%(28/145)；53.1％(2 6/49)，7.7%(8/104)。54株耐多药菌株(multidrug-resistant tuberculosis，MDR-TB) 中，有29株同时合并PZA耐药(53.7%)，99株非耐多药菌株中，有5株PZA耐药(5.1%)，差异 有统计学意义(χ2=47.854，P<0.05)。经logistic回归分析，Sm耐药、MDR-TB是P ZA耐药的危险因素，OR值分别为0.270(95%　CI：0.091～0.802)，0.281(95%CI：0.08 7～0.911)。结论 MDR-TB中PZA耐药率较高，PZA的耐药性与MDR- TB及Sm的耐药性有关联，应重视对MDR患者进行PZA药敏试验。
Abstract:
Objective To research the pyrazinamide drug sus ceptibility of Mycohacterium tuberculosis，and provide reference for clinica l medication and prevention．Methods Bactec MGIT 960 syst em was used to test the resistance of isoniazid，rifampicin，ethambutol，strepto mycin and pyrazinamide for 153 strains of Mycobacterium tuberculosis．〖WT5 ”HZ〗Results Of 153 Mycobacterium tuberculosis，34 were resista nt to PZA，and the resistant rate was 22.2%．There was no PZA single drug resis tance．Among patients with and without INH resistance，RFP resistance，EMB resis tance and Sm resistance，the proportions of PZA resistance were respectively 40 .5%(34/84) vs 0％(0/69)，47.5%(29/61) vs 5.4%(5/92)，75%(6/8) vs 19.3%(28/14 5)，53.1％(26/49) vs 7.7%(8/104)．Among the 54 multidrug-resistant (MDR) stra ins 53.7% were resistant to PZA，which was significantly higher than 5.1％(5/9 9) among the nonMDR-TB strains (χ2=47.854，P<0.05)．In multivariate lo gistic analysis，resistance to Sm (OR=0.270， 95%CI：0.091～0.802) and MDR-T B (OR=0.281，95%CI：0.087～0.911) were risk factors to PZA resistance．〖WT5 ”HZ〗Conclusion The PZA resistance rate among MDR-TB isolates was high．PZA resistance would be associated with SM resistance and MDR-TB．The dru g susceptibility test for PZA is very important to MDR-TB patients．

参考文献/References:

［1］ World Health Organization．Global tuberculosis repo-rt of 2015： Technical appendix on methods used to estimate the global burden of disease caus ed by TB［Z］．Geneva：World Health Organization，2015．
［2］ Mitchison DA．The action of antituberculosis drugs in short-course chemo therapy［J］．Tubercle，1985，66(3)：219-225．
［3］ Whitfield MG，Soeters HM，Warren RM，et al．A gGlobal perspective on pyra zinamide resistance：systematic review and meta-analysis［J］．PLoS One，2015， 28：10(7)：e0133869．
［4］ 胡严杰，黄海荣．结核分枝杆菌对吡嗪酰胺耐药的检测方法研究与进展［J］．中国 防痨杂志，2016，38(9)：761-764． Hu YJ，Huang HR.Progress of pyrazinamide-resistance Mycobacteriu m tuberculosis detection［J］．Chin J Antituberc，2016，38(9)：761-764．
［5］ Cui Z，Wang J，Lu J，et al．Evaluation of methods for testing the suscept ibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide［J］ ．J Clin Microbiol，2013，51(5)：1374-1380．
［6］ Chiu YC，Huang SF，Yu KW，et al．Characteristics of pncA mutations in mul tidrug-resistant tuberculosis in Taiwan［J］．BMC Infectious Diseases，2011，1 1(1)：240．
［7］ 张国钦，商 健，张玉华，等．天津市城区肺结核患者对吡嗪酰胺耐药的现状及特 征［J］．中国防痨杂志，2015，37(5)：508-513． Zhang GQ，Shang J，Zhang YH，et al.Prevalence and characteristic of Pyrazinamide resistance among pulmonary tuberculosis patients in urban area in Tianjin［J］．Chin J Antituberc，2015，37(5)：508-513．
［8］ Xia Q，Zhao LL，Li F，et al．Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang，China［J］．Antimicrob Agents Chemother，2015，59(3)：1 690-1695．
［9］ Kurbatova EV，Cavanaugh JS，Dalton T，et al．Epidemiology of pyrazinamide -resistant tuberculosis in the United States，1999～2009［J］．Clin Infect Dis ，2013，57(8)：1081-1093．
［10］ Jonmalung J， Prammananan T， Leechawengwongs M，et al．Surveill ance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium t uberculosis isolates from Siriraj Hospital，Thailand［J］．BMC Microbiol，2010 ，10(1)：223．
［11］ Simons SO，van Ingen J，van der Laan T，et al．Validation of pncA gene s equencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide［J］．J Cl in Microbiol，2012，50(2)：428-434

相似文献/References:

[1]杨 健,王西娣,陈美玲,等.2013～2015年陕西地区结核分枝杆菌对利福平耐药性及rpoB基因突变的相关研究[J].现代检验医学杂志,2016,31(02):53.[doi:10.3969/j.issn.1671-7414.2016.02.016]
　YANG Jian,WANG Xi-di,CHEN Mei-ling,et al.Related Research on Resistance of Mycobacterium Tuberculosis to Rifampin and rpoB Gene Mutations in Shaanxi from 2013 to 2015[J].Journal of Modern Laboratory Medicine,2016,31(03):53.[doi:10.3969/j.issn.1671-7414.2016.02.016]
[2]吴晓康,周维肖,冯 楠,等.影响TB-IGRA检测结果的因素分析及应对措施[J].现代检验医学杂志,2018,33(04):154.[doi:10.3969/j.issn.1671-7414.2018.04.043]
　WU Xiao-kang,ZHOU Wei-xiao,FENG Nan,et al.Analysis of Factors Influencing TB-IGRA Detection Results and Solutions[J].Journal of Modern Laboratory Medicine,2018,33(03):154.[doi:10.3969/j.issn.1671-7414.2018.04.043]
[3]谭玉华,朱应竹,江 燚,等.时间分辨免疫荧光法检测结核感染T细胞释放γ-干扰素的方法建立及初步临床应用[J].现代检验医学杂志,2018,33(06):21.[doi:10.3969/j.issn.1671-7414.2018.06.006]
　TAN Yu-hua,ZHU Ying-zhu,JIANG Yi,et al.Establishment and Preliminary Clinical Application of Interferon Gamma Release Assays for T Cells Infected With Mycobacterium Tuberculosis Based on Time-Resolved Fluoroimmunoassay[J].Journal of Modern Laboratory Medicine,2018,33(03):21.[doi:10.3969/j.issn.1671-7414.2018.06.006]
[4]田斌,文岚,刘燕萍,等.QFT-GIT对儿童肺结核临床诊断价值的meta分析[J].现代检验医学杂志,2019,34(01):89.[doi:10.3969/j.issn.1671-7414.2019.01.023]
　TIAN Bin,WEN Lan,LIU Yan-ping,et al.Clinical Usefulness of QuantiFERON-TB Gold In-Tube(QFT-GIT) Te st for Tuberculosis Diagnosis in Children：A Systematic Review[J].Journal of Modern Laboratory Medicine,2019,34(03):89.[doi:10.3969/j.issn.1671-7414.2019.01.023]
[5]丁　磊,徐俊驰,邱文娜,等.结核分枝杆菌耐药机制和治疗的最新研究进展[J].现代检验医学杂志,2021,36(02):1.[doi:doi:10.3969/j.issn.1671-7414.2021.02.001]
　DING Lei,XU Jun-chi,QIU Wen-na,et al.Latest Research Progress on the Drug Resistance Mechanism and Treatment of Mycobacterium Tuberculosis[J].Journal of Modern Laboratory Medicine,2021,36(03):1.[doi:doi:10.3969/j.issn.1671-7414.2021.02.001]
[6]李　津a,李昌锦b,杨　洁b,等.Geno-typeMTBDRplus分子线性探针杂交技术在结核病诊断与耐药性检测中的应用价值[J].现代检验医学杂志,2021,36(04):119.[doi:10.3969/j.issn.1671-7414.2021.04.025]
　LI-jina,LI Chang-jinb,YANG Jieb,et al.Value of Geno-type MTBDRplus Molecular Linear Probe Hybridization inTuberculosis Diagnosis and Drug Resistance Detection[J].Journal of Modern Laboratory Medicine,2021,36(03):119.[doi:10.3969/j.issn.1671-7414.2021.04.025]

备注/Memo

备注/Memo:
作 者简介：张 洁(1985-)，女，硕士，主管检验师，研究方向：耐药结核菌，E-m ail：zhangjie218@163.com。 齐红伟(1983-)，本科，主管检验师，E-mail：489641049@qq.co m，共同第一作者。
通讯作者：武文清，副主任医师，所长，北京防痨协会监事长，E mail：wuwenqing1961@126.com。
更新日期/Last Update: 2017-06-25